Logo image of RGNX

REGENXBIO INC (RGNX) Stock Fundamental Analysis

NASDAQ:RGNX - Nasdaq - US75901B1070 - Common Stock - Currency: USD

8.7  +0.02 (+0.23%)

After market: 8.7 0 (0%)

Fundamental Rating

4

RGNX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. RGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, RGNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RGNX had negative earnings in the past year.
RGNX had a negative operating cash flow in the past year.
In the past 5 years RGNX reported 4 times negative net income.
In the past 5 years RGNX reported 4 times negative operating cash flow.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.12%, RGNX is in the better half of the industry, outperforming 64.16% of the companies in the same industry.
With a decent Return On Equity value of -57.51%, RGNX is doing good in the industry, outperforming 61.29% of the companies in the same industry.
Industry RankSector Rank
ROA -32.12%
ROE -57.51%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

RGNX has a better Gross Margin (79.12%) than 85.13% of its industry peers.
In the last couple of years the Gross Margin of RGNX has declined.
The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
RGNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RGNX has more shares outstanding
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.66, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
RGNX has a Altman-Z score (-1.66) which is in line with its industry peers.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.66
ROIC/WACCN/A
WACC9.68%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.93 indicates that RGNX has no problem at all paying its short term obligations.
With a Current ratio value of 2.93, RGNX is not doing good in the industry: 65.59% of the companies in the same industry are doing better.
A Quick Ratio of 2.93 indicates that RGNX has no problem at all paying its short term obligations.
RGNX has a Quick ratio of 2.93. This is in the lower half of the industry: RGNX underperforms 64.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.66% over the past year.
RGNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 80.69%.
Measured over the past years, RGNX shows a quite strong growth in Revenue. The Revenue has been growing by 18.81% on average per year.
EPS 1Y (TTM)46.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.02%
Revenue 1Y (TTM)80.69%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%469.79%

3.2 Future

The Earnings Per Share is expected to grow by 15.99% on average over the next years. This is quite good.
Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 48.76% on average per year.
EPS Next Y98.76%
EPS Next 2Y17.99%
EPS Next 3Y11.72%
EPS Next 5Y15.99%
Revenue Next Year284.56%
Revenue Next 2Y78.04%
Revenue Next 3Y53.22%
Revenue Next 5Y48.76%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.99%
EPS Next 3Y11.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENXBIO INC

NASDAQ:RGNX (7/14/2025, 8:01:51 PM)

After market: 8.7 0 (0%)

8.7

+0.02 (+0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners88.08%
Inst Owner Change0%
Ins Owners7.25%
Ins Owner Change5.31%
Market Cap438.39M
Analysts84.44
Price Target32.39 (272.3%)
Short Float %13.19%
Short Ratio5.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.99%
Min EPS beat(2)-75.63%
Max EPS beat(2)13.65%
EPS beat(4)2
Avg EPS beat(4)-10.98%
Min EPS beat(4)-75.63%
Max EPS beat(4)20.28%
EPS beat(8)3
Avg EPS beat(8)-8.3%
EPS beat(12)4
Avg EPS beat(12)-7.71%
EPS beat(16)5
Avg EPS beat(16)-8.19%
Revenue beat(2)0
Avg Revenue beat(2)-13.43%
Min Revenue beat(2)-14.42%
Max Revenue beat(2)-12.44%
Revenue beat(4)1
Avg Revenue beat(4)-7.79%
Min Revenue beat(4)-14.42%
Max Revenue beat(4)0.57%
Revenue beat(8)2
Avg Revenue beat(8)-17.11%
Revenue beat(12)3
Avg Revenue beat(12)-15.83%
Revenue beat(16)4
Avg Revenue beat(16)-14.03%
PT rev (1m)-0.78%
PT rev (3m)-4.03%
EPS NQ rev (1m)-3.29%
EPS NQ rev (3m)-16.8%
EPS NY rev (1m)90.02%
EPS NY rev (3m)87.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.8
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-2.77
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS3.11
BVpS5.44
TBVpS5.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.12%
ROE -57.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.12%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.16%
Cap/Sales 1.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z -1.66
F-Score5
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.02%
EPS Next Y98.76%
EPS Next 2Y17.99%
EPS Next 3Y11.72%
EPS Next 5Y15.99%
Revenue 1Y (TTM)80.69%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%469.79%
Revenue Next Year284.56%
Revenue Next 2Y78.04%
Revenue Next 3Y53.22%
Revenue Next 5Y48.76%
EBIT growth 1Y40.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.99%
EBIT Next 3Y20.43%
EBIT Next 5Y19.08%
FCF growth 1Y66.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.85%
OCF growth 3YN/A
OCF growth 5YN/A